Sangamo Therapeutics Announces First Quarter 2025 Earnings Call

5/6/25 4:35:00 PM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $SGMO alert in real time by email

Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced that the company has scheduled the release of its first quarter 2025 financial results after the markets close on Monday, May 12, 2025.

The company will hold a conference call at 4:30 p.m. Eastern on Monday, May 12, which will remain open to the public. During the conference call, the company will review its financial results and provide business updates.

Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participants will be given the option to either dial into the call with the number and unique passcode provided, or to use the dial-out option to connect their phone instantly. The link to access the live webcast can also be found on the Sangamo Therapeutics website in the Investors and Media section under Events.

A replay will be available following the conference call, accessible under Events.

About Sangamo Therapeutics

Sangamo Therapeutics is a genomic medicine company dedicated to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases who do not have adequate or any treatment options. Sangamo believes that its zinc finger epigenetic regulators are ideally suited to potentially address devastating neurological disorders and that its capsid discovery platform can expand delivery beyond currently available intrathecal delivery capsids, including in the central nervous system. Sangamo's pipeline also includes multiple partnered programs and programs with opportunities for partnership and investment. To learn more, visit www.sangamo.com and connect with us on LinkedIn and X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250506737112/en/

Investor Relations

Louise Wilkie

[email protected]

Media Inquiries

Melinda Hutcheon

[email protected]

Get the next $SGMO alert in real time by email

Date	Price Target	Rating	Analyst
12/13/2024	$7.00	Hold → Buy	Truist
12/10/2024	$10.00	Buy	H.C. Wainwright
11/3/2023	$6.00 → $2.00	Outperform → Sector Perform	RBC Capital Mkts
4/28/2023	$5.00 → $1.50	Neutral → Underperform	BofA Securities
2/27/2023	$16.00	Neutral → Outperform	Wedbush
1/6/2023	$8.00 → $5.00	Buy → Neutral	BofA Securities
6/13/2022	$5.00	Neutral	Wedbush

Sangamo Therapeutics Announces First Quarter 2025 Earnings Call

Chat with this insight

Recent Analyst Ratings for
$SGMO

$SGMO
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Parker H Stewart was granted 25,000 shares, increasing direct ownership by 29% to 112,600 units (SEC Form 4)

Director Smith Karen L. was granted 25,000 shares, increasing direct ownership by 32% to 102,100 units (SEC Form 4)

Director Carey Robert was granted 25,000 shares, increasing direct ownership by 34% to 99,600 units (SEC Form 4)

Sangamo Therapeutics Announces First Quarter 2025 Earnings Call

Chat with this insight

Recent Analyst Ratings for $SGMO

$SGMO Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Parker H Stewart was granted 25,000 shares, increasing direct ownership by 29% to 112,600 units (SEC Form 4)

Director Smith Karen L. was granted 25,000 shares, increasing direct ownership by 32% to 102,100 units (SEC Form 4)

Director Carey Robert was granted 25,000 shares, increasing direct ownership by 34% to 99,600 units (SEC Form 4)

Recent Analyst Ratings for
$SGMO

$SGMO
Insider Trading